The Dubin Breast Center of The Tisch Cancer Institute at the Mount Sinai Health System celebrated its 12th anniversary with its annual gala on Monday, December 12.
Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped
As medical schools across the country grapple with the arduous process of revising their curricula to be anti-racist, students at the Icahn School of Medicine at Mount Sinai have turned a critical eye on the very textbooks that have trained medical students for years.
Researchers at The Tisch Cancer Institute uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results published in JAMA Network Open in December.
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the publication of new real-world evidence (RWE) in Primary Care and Community Health demonstrating the Company’s KidneyIntelX bioprognostic™ test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease (DKD) being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs.
The Icahn School of Medicine at Mount Sinai announced today the appointment of two new Laureates as part of its Biomedical Laureates Program, bringing the total to five appointments for this year and furthering its institutional commitment to broadening faculty diversity and mentorship opportunities.
Past social trauma is encoded by a population of stress/threat-responsive brain cells that become hyperactivated during subsequent interaction with non-threatening social targets. As a consequence, previously rewarding social targets are now perceived as social threats, which promotes generalized social avoidance and impaired social reward processing that can contribute to psychiatric disorders.
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.
The polycystic kidney disease (PKD) Foundation—the only organization in the U.S. dedicated solely to finding treatments and a cure for PKD recently named Mount Sinai Health System as a PKDF Partner Clinic for their desire to support patients with Autosomal Dominant PKD (ADPKD).
The Mount Sinai Health System has officially unveiled its new, state-of-the-art Mount Sinai Phillips School of Nursing (PSON) campus, located at 126th Street and Lexington Avenue.
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.
A team of geriatricians at Mount Sinai’s Brookdale Department of Geriatrics and Palliative Medicine has been awarded $1.25 million from the Health Resources and Services Administration and the Keith Haring Foundation to expand Mount Sinai’s interdisciplinary model of care for older patients living with HIV.
A gene recognized as the strongest risk factor for Alzheimer’s disease (AD) alters the way cholesterol moves around the brain and as we age, this altered movement likely contributes to loss of learning and memory, a team of researchers from the Icahn School of Medicine at Mount Sinai and the Massachusetts Institute of Technology (MIT) reports.
Researchers at the Icahn Mount Sinai have identified 35 genes that are particularly highly expressed in people with long-term Lyme disease. These genes could potentially be used as biomarkers to diagnose patients with the condition, which is otherwise difficult to diagnose and treat. The findings, published November 15 in the journal Cell Reports Medicine, may also lead to new therapeutic targets. The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease.
A team of equity researchers at Mount Sinai’s Institute for Health Equity Research (IHER) will use a $2.5 million grant from the National Institutes of Health (NIH) to assess how unequal access to health care impacts patient health.
Mount Sinai Health System was celebrated by the U.S. Department of Health and Human Services (HHS) at the 2022 United Nations Climate Change Conference (COP27) on Thursday, November 10, for pledging ongoing action to decarbonize the health care sector and make health care facilities more resilient to the effects of climate change.
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) has recognized Mount Sinai Beth Israel for achieving meritorious outcomes for surgical patient care in 2021.
Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.
A novel metric that estimates our “burden,” or cumulative exposure, to a family of thousands of synthetic chemicals that we encounter in everyday life with potentially adverse health impacts, has been created by a team of researchers at Mount Sinai.
Mount Sinai researchers have catalogued thousands of sites in the brain where RNA is modified throughout the human lifespan in a process known as adenosine-to-inosine (A-to-I) editing, offering important new avenues for understanding the cellular and molecular mechanisms of brain development and how they factor into both health and disease.
The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer. The latest installment of $225,000 brings the total to almost $2 million over the past nine years. It will fund research into the immune microenvironment of triple-negative breast cancer in order to identify new strategies to enhance cancer-fighting immune responses for this aggressive breast cancer, which traditionally has few options for treatment.
Findings suggest exclusions to Medicaid because of immigration status may increase risk for maternal health care disparities in some immigrant populations
A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly attacking the cancer—provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York. The findings were published October 11, 2022 in the journal Cancer Immunology Research [https://doi.org/10.1158/2326-6066.CIR-21-1075]. The study involved a twist on a type of therapy that uses immune cells known as CAR T cells. CAR T cells in current clinical use are engineered to recognize cancer cells directly and have successfully treated several blood cancers. But there have been challenges that prevent their effective use in many solid tumors.
Harlem-based Corbin Hill Food Project secured an additional $500k funding for its Food as Medicine project in partnership with Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai, and the Institute for Family Health's Bronx Health REACH Project, bringing the total funding to $1M.
Stem cell-derived neurons from combat veterans with post-traumatic stress disorder (PTSD) react differently to a stress hormone than those from veterans without PTSD, a finding that could provide insights into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
Researchers from the Icahn School of Medicine at Mount Sinai have learned that the way the brain processes the complex emotion of regret may be linked to an individual’s ability to cope with stress, and altered in psychiatric disorders like depression.
Yvette Calderon, MD, MS, Chair of Emergency Medicine at Mount Sinai Beth Israel and Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With her election, Mount Sinai has 26 faculty members in the NAM.
Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position, effective Sunday, January 1, 2023. Dr. Fuster will continue in his roles as Physician-in-Chief of The Mount Sinai Hospital and as the Richard Gorlin, MD/Heart Research Foundation Professor at the Icahn School of Medicine at Mount Sinai.
The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Program that will benefit the diverse patient population Mount Sinai serves by accelerating the development of new treatments for leading health conditions, including cardiorespiratory and psychiatric disorders, diabetes, malignancies, and infectious diseases.
Researchers have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor cells.
Researchers have identified the gene TDRD7 as a key regulator against influenza A virus (IAV), which causes respiratory tract infections in 5 to 20 percent of the human population.